← All trials
NCT04609826
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 26, 2020
- Primary completion
- Sep 28, 2023
- Completion date
- Sep 28, 2023
- First posted
- Oct 30, 2020
- Last posted
- Dec 30, 2020
- Enrollment
- 120
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Janssen Pharmaceutica NVLead sponsor
- Janssen Pharmaceutica NVStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.